These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Management of metabolic complications and cardiovascular risk in HIV-infected patients. Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187 [TBL] [Abstract][Full Text] [Related]
4. Endothelial function in HIV-infected patients with low or mild cardiovascular risk. Blanco JJ; García IS; Cerezo JG; de Rivera JM; Anaya PM; Raya PG; García JG; López JR; Hernández FJ; Rodríguez JJ J Antimicrob Chemother; 2006 Jul; 58(1):133-9. PubMed ID: 16702174 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk among HIV-positive patients on antiretroviral therapy. Aberg JA J Int Assoc Physicians AIDS Care (Chic); 2003 Sep; 2 Suppl 2():S24-39. PubMed ID: 14569635 [TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy with heart. Randell P; Moyle G Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610 [TBL] [Abstract][Full Text] [Related]
7. HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults. Lipshultz SE; Mas CM; Henkel JM; Franco VI; Fisher SD; Miller TL Expert Rev Anti Infect Ther; 2012 Jun; 10(6):661-74. PubMed ID: 22734956 [TBL] [Abstract][Full Text] [Related]
8. Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. Guzmán-Fulgencio M; Medrano J; Rallón N; Echeverria-Urabayen A; Miguel Benito J; Restrepo C; García-Álvarez M; Vispo E; San Roman J; Sánchez-Piedra C; Soriano V; Resino S J Infect; 2011 Nov; 63(5):382-90. PubMed ID: 21855573 [TBL] [Abstract][Full Text] [Related]
9. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. Baekken M; Os I; Sandvik L; Oektedalen O J Hypertens; 2008 Nov; 26(11):2126-33. PubMed ID: 18854751 [TBL] [Abstract][Full Text] [Related]
10. Endothelial and platelet function alterations in HIV-infected patients. Gresele P; Falcinelli E; Sebastiano M; Baldelli F Thromb Res; 2012 Mar; 129(3):301-8. PubMed ID: 22192157 [TBL] [Abstract][Full Text] [Related]
11. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients. Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular disease and toxicities related to HIV infection and its therapies. Zareba KM; Miller TL; Lipshultz SE Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661 [TBL] [Abstract][Full Text] [Related]
13. First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006). Carosi G; Quiros-Roldan E; Torti C; Antinori A; Bevilacqua M; Bonadonna RC; Bonfanti P; Castagna A; Cauda R; d'Arminio-Monforte A; Di Gregorio P; Di Perri G; Esposito R; Fatuzzo F; Gervasoni C; Giannattasio C; Guaraldi G; Lazzarin A; Lo Caputo S; Maggi P; Mazzotta F; Moroni M; Prestileo T; Ranieri R; Rizzardini G; Russo R; Galli M; Infection; 2007 Jun; 35(3):134-42. PubMed ID: 17565453 [TBL] [Abstract][Full Text] [Related]
14. Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection. Barbaro G Clin Ter; 2008; 159(1):51-5. PubMed ID: 18399263 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences. Neumann T; Woiwod T; Neumann A; Ross B; Von Birgelen C; Volbracht L; Brockmeyer NH; Gerken G; Erbel R Eur J Med Res; 2004 Feb; 9(2):55-60. PubMed ID: 15090290 [TBL] [Abstract][Full Text] [Related]
16. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan. Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular disease and HIV infection: host, virus, or drugs? Martínez E; Larrousse M; Gatell JM Curr Opin Infect Dis; 2009 Feb; 22(1):28-34. PubMed ID: 19532078 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus. Magen E; Elbirt D; Sthoeger Z Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients. Fisher SD; Kanda BS; Miller TL; Lipshultz SE Am J Cardiovasc Drugs; 2011 Dec; 11(6):383-94. PubMed ID: 22149317 [TBL] [Abstract][Full Text] [Related]
20. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. Arildsen H; Sørensen KE; Ingerslev JM; Østergaard LJ; Laursen AL HIV Med; 2013 Jan; 14(1):1-9. PubMed ID: 22639788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]